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Summary: In population-based cancer studies, it is often interesting to compare cancer survival between different
populations. However, in such studies, the exact causes of death are often unavailable or unreliable. Net survival
methods were developed to overcome this difficulty. Net survival is the survival that would be observed if the disease
under study were the only possible cause of death. The Pohar-Perme estimator (PPE) is a non-parametric consistent
estimator of net survival. In this paper, we present a log-rank-type test for comparing net survival functions (as
estimated by PPE) between several groups. We put the test within the counting process framework to introduce
the inverse probability weighting procedure as required by the PPE. We built a stratified version to control for
categorical covariates that affect the outcome. We performed simulation studies to evaluate the performance of this
test and worked an application on real data.
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1. Introduction
Net survival, the survival associated with the excess mortality hazard, is the survival that
would be observed in a hypothetical world where the disease of interest would be the only
possible cause of death. The observed survival, which is more frequently used, is the result
of two main survival components: one related to death from the disease and another to
death from all other causes (Este`ve et al., 1990; Perme, Stare, and Este`ve, 2012). On the
one hand, the observed survival does not distinguish between death from the disease of
interest (or excess mortality) and death from other causes. On the other hand, net survival
evaluates the burden of the disease independently of the general-population mortality; i.e.,
the mortality from other causes as given by life tables. In cancer research, the idea of cancer
net survival is the study of the proportion of deaths due directly or indirectly to cancer. This
epidemiological indicator is routinely estimated by cancer registries and population-based
studies such as the EUROCARE program (De Angelis et al., 2014), the US SEER program
(Howlader et al., 2011), or the CONCORD program (Allemani et al., 2015). It is crucial
for comparisons between different populations (Perme et al., 2012; Danieli et al., 2012). For
instance, in comparing the patterns of care between countries, it is essential to take into
account the general-population mortality because of its impact on the observed survival.
In population-based studies, the exact causes of death are often unavailable and, when
available, often difficult to link to a given disease (Berkson and Gage, 1950). Net survival
methods were developed to overcome this difficulty (Este`ve et al., 1990). Historically, several
non-parametric estimators have been proposed to estimate net survival (Ederer and Heise,
1959; Ederer, Axtell, and Cutler, 1961; Hakulinen, 1982). Nevertheless, in 2012, Perme et al.
(2012) considered that, in most cases, these estimators do not estimate net survival. These
authors proposed then a non-parametric estimator that corrects Ederer II estimator (Ederer
and Heise, 1959) now known to be biased because of informative censoring. For instance, the
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excess mortality and mortality from other causes are both age-dependent; this leads to an
informative censoring. Perme et al. used population mortality to weight and correct for the
subjects who leave the sample due to deaths from other causes. Later, Danieli et al. (2012)
showed by simulation that the Pohar-Perme estimator (PPE) is a consistent non-parametric
estimator of net survival that may be preferred to other non-parametric estimators. The PPE
estimates a hypothetical quantity that allows comparisons between populations. However,
to the best of our knowledge, comparing distributions of net survival over a given period in
the non-parametric framework is not possible yet; only a comparison between two estimates
at a given time t is currently possible with a classical Z-test. Besides, in the parametric
framework, the comparison of net survival between two groups or more may use a likelihood
ratio test in the context of a multivariate excess mortality model (see e.g., Remontet et al.,
2007), but this requires a complex model building strategy.
In this paper, we propose a log-rank-type test to compare distributions of net survival as
estimated by the PPE between two groups or more over a defined follow-up period. This
choice was made for several reasons. First, the log-rank test (Mantel, 1966; Peto and Peto,
1972) is very commonly used to compare distributions of observed survival between at
least two groups. Second, the log-rank test uses the cumulative hazard function and can
be represented with stochastic processes (Aalen, Borgan, and Gjessing, 2008; Fleming and
Harrington, 2011; Andersen, Borgan, Gill, and Keiding, 1993). Finally, because the PPE is
written with stochastic processes on the cumulative hazard scale, the log-rank test allows an
easy introduction of the weights of the PPE into the corresponding counting processes.
In Section 2, we present the way of building the proposed log-rank-type test and, in Section 3,
the stratified version of this test. Section 4 presents a simulation study where we investigated
the performance of this test. Section 5 provides an application to colorectal cancer data. We
conclude this paper with a brief discussion.
A test to compare net survival distributions 3
2. A log-rank-type test for k > 2 groups
The proposed test compares the distributions of net survival (as estimated by the PPE)
(Perme et al., 2012) between k > 2 groups over a defined follow-up period. We assume
that the observations concern nh patients from h groups, with h ∈ [[1; k]] and k > 2. Let
n =
k∑
h=1
nh denote the total number of patients. We assume also that (Fleming, Harrington,
and O’Sullivan, 1987)
∀h ∈ [[1; k]], lim
n→∞
nh
n
= αh;αh ∈ ]0; 1[ .
Under these assumptions: lim
n→∞
min
h
nh =∞.
2.1 Notations and model
We consider that Th,i, the time to death of each patient i in group h, is the minimum of two
distinct times: TPh,i due to the “population hazard” and TEh,i due to the “excess hazard”.
Let Ch,i be the censoring time and Uh,i = min(Th,i, Ch,i) the follow-up time of patient i.
δ˜h,i denotes the failure indicator equal to 1 when the true failure time Th,i is observed and
0 when patient i is censored (the use of ∼ avoids a possible confusion with the notation of
Kronecker delta). Each patient i in a group h has covariates denoted by vector Xh,i. Dh,i
is a sub-vector of Xh,i that describes all the demographic covariates such that Xh,i \Dh,i
and TPh,i are independent. Besides, we adopt the same set of assumptions as in Perme et al.
(2012):
a) (TPh,i , TEh,i, Ch,i,Xh,i)h,i are mutually independent;
b) (TPh,i, TEh,i, Ch,i,Xh,i)i have the same distribution;
c) TEh,i and TPh,i are conditionally independent given Xh,i; (1)
d) censoring times Ch,i are independent of pair (Th,i,Xh,i).
Further, we assume that the censoring process is non-informative; i.e., SC,h(t) := P (Ch,i > t)
(∀i ∈ [[1;n]], ∀h ∈ [[1; k]]). The observed data are given by (Uh,i, δ˜h,i,Xh,i)h,i for each pa-
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tient i in group h. The conditional net survival function of TEh,i that corresponds to each
patient i of group h is denoted by S˜E,h,i(t) = P (TEh,i > t | Xh,i). The corresponding
conditional cumulative excess hazard is denoted by Λ˜E,h,i. In the same way, we can define
the conditional population all-cause survival as S˜P,h,i(t) = P (TPh,i > t | Xh,i) which equals
P (TPh,i > t | Dh,i) because Xh,i \Dh,i and TPh,i are assumed to be independent. The
corresponding conditional population all-cause cumulative hazard is denoted by Λ˜P,h,i. We
use life tables to calculate the conditional population all-cause hazard functions according to
individual demographic covariates such as age, sex, and year of diagnosis that can be found
in Dh,i. We assume that these life tables describe adequately the all-cause death rates in the
study population (Perme et al., 2012). Further, for each group h, the net survival function is
defined as SE,h(t) = E(S˜E,h,1(t)); thus, we have SE,h(t) = P (TEh,1 > t). Let ΛE,h denote the
corresponding cumulative excess hazard. In the same way, we define the population all-cause
survival by SP,h(t) = P (TPh,1 > t) and the corresponding population all-cause cumulative
hazard by ΛP,h. Note that λ˜E,h,i, λ˜P,h,i, λE,h, and λP,h denote the instantaneous hazards
related to Λ˜E,h,i, Λ˜P,h,i, ΛE,h, and ΛP,h, respectively. From assumption (1.c), it follows that
the conditional observed mortality hazard is the sum of the conditional population mortality
hazard plus the conditional excess mortality hazard: λ˜P,h,i(t) + λ˜E,h,i(t).
Besides, we use the following additional assumptions to prove the asymptotic χ2 distribution
of our test statistic under the null hypothesis:
a)
∫ T
0
SE,h(s)λ
2
E,h(s)ds <∞;
b) ∀h ∈ [[1; k]], E(
1
S˜P,h,1(T )3
) <∞; (2)
c) ∀h ∈ [[1; k]], E(
∫ T
0
λ˜P,h,1(s)
2ds
S˜P,h,1(s)3
) <∞;
where T is a constant that represents the maximum follow-up time. Note that these assump-
tions require that T be not too long vs. TP or TE. For instance, (2.a) is not satisfied if TE < T
(a.s.) and (2.b) is not satisfied if TP < T (a.s.).
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2.2 The log-rank-type statistic
The usual log-rank test compares k cumulative observed hazard functions over [0, T ], where
[0, T ] denotes the period of observation. The k-sample log-rank test is a test for the null
hypothesis (H0) : ∀t ∈ [0, T ] , Λ1(t) = . . . = Λk(t) where k > 2 is the number of groups
to compare and Λh (h ∈ [[1; k]]) the cumulative observed hazard. Using counting process
representations (see e.g., Andersen et al., 1993), the log-rank test is based on the following
statistic
Zh(T ) =
∫ T
0
1(Y.(s) > 0)dNh(s)−
∫ T
0
1(Y.(s) > 0)
Yh(s)
Y.(s)
dN.(s),
where h ∈ [[1; k]], Nh,i(s) = 1(Th,i 6 s, Th,i 6 Ch,i) = 1(Uh,i 6 s, δ˜h,i = 1),
Yh,i(s) = 1(Th,i > s, Ch,i > s), Nh(s) =
nh∑
i=1
Nh,i(s), Yh(s) =
nh∑
i=1
Yh,i(s), Y.(s) =
k∑
h=1
Yh(s)
and N.(s) =
k∑
h=1
Nh(s) for k > 2. Zh(T ) represents the difference between the number of
observed deaths in group h and the corresponding expected values.
Here, our goal is to test the null hypothesis
(H0) : ∀t ∈ [0, T ] , ΛE,1(t) = . . . = ΛE,k(t)
where k > 2. More precisely, we want to compare k cumulative excess hazard functions
over this period using PPE (Perme et al., 2012). The PPE, ΛˆE,h, is a consistent estimator of
ΛE,h. It corrects Ederer II estimator for the subjects who leave the sample due to deaths from
other causes using the inverse probability weighting procedure (Robins, 1993). The weights
are the survival probabilities of death from other causes that are applied to the counting
and the at-risk processes. More precisely, we have dNwh,i(s) =
dNh,i(s)
S˜P,h,i(s)
, Y wh,i(s) =
Yh,i(s)
S˜P,h,i(s)
,
Nwh (s) =
nh∑
i=1
Nwh,i(s), and Y
w
h (s) =
nh∑
i=1
Y wh,i(s) for h ∈ [[1; k]] and k > 2. The PPE is given
by
∀k > 2, ∀h ∈ [[1; k]], ΛˆE,h(t) =
∫ t
0
dNwh (s)
Y wh (s)
−
∫ t
0
∑nh
i=1 Y
w
h,i(s)λ˜P,h,i(s)ds
Y wh (s)
.
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To build our log-rank-type test, we first have to consider another stochastic process related to
the expected number of deaths from cancer NE,h(s) =
nh∑
i=1
NE,h,i(s) where NE,h,i(s) is given
by Nh,i(s) −
∫ s
0
Yh,i(u)λ˜P,h,i(u)du for each patient i and each group h ∈ [[1; k]]. Second, we
use the same weighting procedure as in the PPE. The expected weighted number of deaths
from cancer is then defined by NwE,h(s) =
nh∑
i=1
NwE,h,i(s) with dN
w
E,h,i(s) =
dNE,h,i(s)
S˜P,h,i(s)
. For
all h ∈ [[1; k]], we now consider the statistic
Zwh (T ) =
∫ T
0
1(Y w. (s) > 0)dN
w
E,h(s)−
∫ T
0
1(Y w. (s) > 0)
Y wh (s)
Y w. (s)
dNwE,.(s), (3)
where Y w. (s) =
k∑
h=1
Y wh (s) and dN
w
E,.(s) =
k∑
h=1
dNwE,h(s) for k > 2.
Note that when k = 2, Zw
1
(T ) is given by∫ T
0
1(Y w. (s) > 0)dN
w
E,1(s)−
∫ T
0
1(Y w. (s) > 0)
Y w
1
(s)
Y w
1
(s) + Y w
2
(s)
(
dNwE,1(s) + dN
w
E,2(s)
)
=
∫ T
0
1(Y w. (s) > 0)
(
Y w
2
(s)
Y w
1
(s) + Y w
2
(s)
dNwE,1(s)−
Y w
1
(s)
Y w
1
(s) + Y w
2
(s)
dNwE,2(s)
)
.
The proposed test may be considered as a “log-rank-type test” because of the similarity
between the two tests. For h ∈ [[1; k]],
dNwE,h(s)
Y wh (s)
is a consistent estimator of the instantaneous
excess hazard at time s, λE,h(s) (Perme et al., 2012). It serves the same purpose as
dNh(s)
Yh(s)
which is a consistent estimator of the observed instantaneous hazard at time s, λh(s).
2.3 Estimate of the variance of Zwh under the null hypothesis
We used the martingale theory to estimate the variance of statistic Zwh (T ) under the null
hypothesis. We started by examining the case where TEh and Xh are independent for each
h ∈ [[1; k]]; i.e., we assumed homogeneity in each group. This strong assumption is usually
made when studying the usual log-rank test (see e.g., Andersen et al., 1993). In practice,
this assumption is frequently violated; for example, when death from cancer is related to a
given sex. Then TE and X are dependent. We will deal with this general case by building a
stratified test we present in the next section.
Consistently with the idea of calculating the estimate of the variance of the PPE (Perme
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et al., 2012), we introduce
Mh,i(s)
def
= Nh,i(s)−
∫ s
0
Yh,i(u)
(
λ˜P,h,i(u) + λE,h(u)
)
du
= NE,h,i(s)−
∫ s
0
Yh,i(u)λE,h(u)du.
Mh,i(s) is a local square integrable martingale with respect to the filtration
Fs = σ (Xh,i, 1(Uh,i 6 u, Uh,i = Th,i) : 0 6 u 6 s; h ∈ [[1; k]]; 1 6 i 6 nh). Its predictable
variation process 〈Mh,i〉 is given by
∫ s
0
Yh,i(u)
(
λ˜P,h,i(u) + λE,h(u)
)
du. Note that S˜P,h,i is
(F0)−measurable so that we can define
dMwh (s)
def
=
nh∑
i=1
dMh,i(s)
S˜P,h,i(s)
= dNwE,h(s)− Y
w
h (s)λE,h(s)ds, (4)
and Mwh (s) is a local square integrable martingale with respect to (Fs)s.
Let ΛE and λE denote ΛE,h and λE,h under the null hypothesis (∀h ∈ [[1; k]]). Then we have
dNwE,.(s) =
k∑
h=1
dNwE,h(s) =
k∑
h=1
dMwh (s) + λE(s)
k∑
h=1
Y wh (s)ds. (5)
Introducing (4) and (5) in formula (3), we obtain under the null hypothesis
Zwh (T ) =
k∑
l=1
∫ T
0
1(Y w. (s) > 0)
(
δhl −
Y wh (s)
Y w. (s)
)
dMwl (s),
δhl being the Kronecker delta. For all h ∈ [[1; k]], Z
w
h are local square integrable martingales
with respect to (Fs)s. We have E〈Z
w
h 〉(T ) <∞ since ∀h ∈ [[1; k]]
E〈Zwh 〉(T ) 6
k∑
l=1
nlE
{∫ T
0
SC,l,1(s)SE(s)
S˜P,l,1
(
λ˜P,l,1(s) + λE(s)
)
ds
}
< ∞ (see Web Appendix
A). So, the Zwh are square integrable over [0, T ].
Because the first and second order moments of the Zwh exist, we have
cov
(
Zwh (T ), Z
w
j (T )
)
= E[Zwh , Z
w
j ](T ),
[Zwh , Z
w
j ](T ) =
k∑
l=1


∫ T
0
1(Y w. (s) > 0)
(
δhl −
Y wh (s)
Y w. (s)
)(
δjl −
Y wj (s)
Y w. (s)
) nl∑
i=1
dNl,i(s)(
S˜P,l,i(s)
)2

 .
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Note that, when k = 2, we have
[Zw
1
, Zw
1
](T ) =
∫ T
0
1(Y w. (s) > 0)


(
Y w
2
(s)
Y w
1
(s) + Y w
2
(s)
)2 n1∑
i=1
dN1,i(s)(
S˜P,1,i(s)
)2
+
(
Y w
1
(s)
Y w
1
(s) + Y w
2
(s)
)
2 n2∑
i=1
dN2,i(s)(
S˜P,2,i(s)
)
2

 .
2.4 The test statistic
Following closely the usual log-rank test (Andersen et al., 1993) and knowing that
k∑
h=1
Zwh (T ) = 0, we propose to test the null hypothesis with the following statistic
Uw(T ) = Zw
0
(T )tΣˆ2,w
0
(T )−1Zw
0
(T ), (6)
where Zw
0
(T ) =
(
Zw
1
(T ), . . . , Zwk−1(T )
)t
and Σˆ2,w
0
is the matrix of general term
σˆ2,wh,j (T ) =
k∑
l=1


∫ T
0
1(Y w. (s) > 0)
(
δhl −
Y wh (s)
Y w. (s)
)(
δjl −
Y wj (s)
Y w. (s)
) nl∑
i=1
dNl,i(s)(
S˜P,l,i(s)
)2


for (h, j) ∈ [[1; k − 1]]2.
Under assumptions (2), we can show that, under the null hypothesis, Uw(T ) ∼ χ2(k − 1)
when n −→∞ (see proof in Web Appendix B).
3. Stratified version of the test
To estimate the variance of Zwh under the null hypothesis, we made the strong assumption
of independence between TE and X. Now we look at the general case where TE and X
can be dependent. We define a partition of the covariate space by (I1, . . . , Im) and assume
that P (TEh > t |Xh) =
m∑
s=1
P (TEh > t | Xh ∈ Is). 1 (Xh ∈ Is), where Xh denotes the
set of covariates in group h. The (Is)16s6m are called strata of one or more covariate. For
example, when death from cancer is related to a given sex, we may consider two strata (men
and women). Thus, we assume homogeneity within each stratum but allow heterogeneity
between strata. We define ΛE,h,s as the cumulative excess hazard that corresponds to the
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net survival function SE,h,s(t) = P (TEh > t |Xh ∈ Is).
We want to test (H0): ∀t ∈ [0, T ] , ∀s ∈ [[1;m]], ΛE,1,s(t) = . . . = ΛE,k,s(t).
We define Y w.,s(u) =
k∑
h=1
Y wh,s(u) with Y
w
h,s(u) =
nh∑
i=1
Yh,i(u)
S˜P,h,i(u)
1(Xh,i ∈ Is). In the same way,
we define dNwE,.,s(u) =
k∑
h=1
dNwE,h,s(u). According to Andersen et al. (1993), we define the
statistics
Zwh,s(T ) =
∫ T
0
1(Y w.,s(u) > 0)dN
w
E,h,s(u)−
∫ T
0
1(Y w.,s(u) > 0)
Y wh,s(u)
Y w.,s(u)
dNwE,.,s(u), (7)
and
σˆ2,wh,j,s(T ) =
k∑
l=1
{∫ T
0
1(Y w.,s(u) > 0)
(
δhl −
Y wh,s(u)
Y w.,s(u)
)(
δjl −
Y wj,s(u)
Y w.,s(u)
)
×
nl∑
i=1
dNl,i(u)(
S˜P,l,i(u)
)21(Xl,i ∈ Is)

 . (8)
We denote for s ∈ [[1;m]] the vectors and matrices with elements given by (7) and (8) by Zw
s
and Σˆ
2,w
s . Then we will test the null hypothesis with the statistic(
m∑
s=1
Z
w
s,0
(T )
)t
.
(
m∑
s=1
Σˆ
2,w
s,0 (T )
)
−1
.
(
m∑
s=1
Z
w
s,0
(T )
)
,
which, under the null hypothesis, has an asymptotic χ2 distribution with (k − 1) degrees
of freedom. Note that, for s ∈ [[1;m]], Zw
s,0
(T ) =
(
Zw
1,s(T ), . . . , Z
w
k−1,s(T )
)t
and Σˆ
2,w
s,0 is the
same matrix as Σˆ
2,w
s without the last row and the last column.
4. Simulations
We evaluated the performance of the proposed log-rank-type test by simulation studies in
cases where TE and X are independent with k = 2 or 3 and where TE and X are dependent
with k = 2.
4.1 Data generation and simulation design
For each patient i, we generated independently covariates sex, age, and G, which represents
the groups (G had k = 2 or k = 3 levels). Covariate sex was generated from a binomial
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distribution with P (man) = P (woman) = 1/2. Covariate G was generated to study balanced
cases (i.e., P (G = 0) = P (G = 1) with k = 2 or P (G = 0) = P (G = 1) = P (G = 2)
with k = 3) or unbalanced cases only (i.e., P (G = 0) = 1/4 and P (G = 1) = 3/4 with
k = 2). Because TP depends on age, we studied 3 scenarios: 1) we generated covariate age
to represent approximately the empirical distribution of ages of colon cancer patients in the
French registries (25 percent aged 40-64 years, 35 percent aged 65-74 years, and 40 percent
aged 75 years and over); 2) we studied a young population using a uniform distribution
between ages 30 and 40; and 3) we studied an old population using a uniform distribution
between ages 65 and 80.
Danieli et al. (2012) have shown that the multivariable modeling estimator, which is based
on the multivariable additive excess hazard model, is a consistent parametric estimator of net
survival after adjustment on demographic covariates. Thus, we generated survival times from
this model. In its classical additive form (Este`ve et al., 1990), the observed hazard related
to the individual time to death Ti is defined as the sum of the instantaneous conditional
population all-cause death hazard and disease excess hazard, λ˜P,i and λ˜E,i. For this, Ti
was generated as follows: first, for each patient i, the time to death due to the population
hazard, TPi, was obtained from the 2004 American life table, survexp.us, stratified by
Di = (agei, sexi), as provided by survival package in R software (Therneau, 2015). Second,
for each patient i, the time to death from cancer, TEi, was obtained from λ˜E,i modeled with
the standard approach (see e.g., Giorgi et al., 2003) and using the inverse transformation
method. More precisely, λ˜E,i(t) = f(t). exp
(
βsex1(sexi = man) +
k−1∑
l=1
βG,l1(Gi = l)
)
where
βsex and βG,l are the log hazard ratios (HR) of the covariates. The baseline hazard function f
was modeled with a generalized Weibull distribution (Belot et al., 2010) as t 7−→
κρκtκ−1
1 +
(ρt)κ
α
with ρ = 0.5, α = 0.2 and κ = 2. The distributions of net survival in the groups defined
by the levels of G vary when the effects of G on the excess mortality vary. More precisely,
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the null hypothesis is true when the HR(s) of G equals 1. Conversely, the farther the HR
is from 1, the more different are the groups in terms of net survival and the farther we
move away from the null hypothesis. When k was equal to 2, the HR of G belonged to
{0.7; 0.8; 0.9; 1; 1.2; 1.4; 1.6}. When k was equal to 3, the HRs of G, (HR1, HR2), belonged
to {(1, 0.7); (1, 1); (1, 1.2); (1, 1.4); (1, 1.6); (0.9, 1.2); (0.8, 1.4); (0.7, 1.6)}. In studying the case
where TE and X are independent, we did not introduce effects of age and sex on the excess
mortality (assumption of homogeneity). Conversely, in studying the case where TE andX are
dependent, we set the HR of sex to 2 and 3 and chose to assume independence with respect
to age. The higher the HR of sex is, the more different are the distributions of the time to
death from cancer between men and women in a given group h. Finally, individual censoring
times Ci were generated from a uniform distribution U [0; b] where the upper boundary b was
selected to obtain approximately 0% or 30% overall censoring levels. Then, each individual’s
observable time to death was Ti = min(TPi , TEi) whereas each individual’s observed time
to death was Ui = min(TPi , TEi, Ci). All subjects still at risk at 5 years were censored.
Moreover, we defined an individual’s hypothetical time to death as the minimum of two
values: the time to death due to the excess mortality and the time to censoring. According
to this time, we obtained another vital status that corresponds to a hypothetical world where
cancer would be the only cause of death. Thus, we could compare our test with the usual log-
rank test applied on “hypothetical data” and consider the latter test as the gold standard.
This is possible only within a simulation framework. We note here that even if cause-specific
data were available for our simulations, no direct gold standard for our log-rank-type test
could be used in the “real world” because the real world is that of competing risks; thus,
still subject to informative censoring.
Each simulation run consisted of 2000 independent samples. Each of them contained 1000
patients.
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4.2 Simulation results
The results obtained without censoring were roughly equivalent to those obtained with 30%
censoring, except regarding power. Actually, the power decreased as the censoring level
increased. Here, we show only the results related to a 30% censoring level (Tables 1, 2
and 3).
In the comparisons between two groups, the estimation of the type I error of our log-rank-
type test was good. In Table 1, at a 5% significance level, the confidence intervals of type
I error estimations contain the nominal level of 5% for our test and the usual log-rank test
applied on hypothetical data. In comparison with the usual log-rank test, our test performed
well in terms of power (Table 1). In the second scenario where the patients are young, the
results of both tests were nearly the same. In the first and third scenarios where the patients
are old (75% of the patients were more than 65 in the first scenario), our test showed a loss
of power.
[Table 1 about here.]
As expected, whatever the scenario, both tests were more powerful when the number of
patients increased from 500 to 2000 (results not shown) and both tests lost power when the
cases were unbalanced (Web Table A).
In the comparisons between three groups, the estimation of the type I error was close to
the nominal level of 5% (Table 2). Table 2 shows that, with the first scenario, our test was
less powerful than the usual log-rank test with hypothetical data, especially when the three
distributions of net survival were not far away from each other ((HR1, HR2) = (1, 0.7) or
(0.9, 1.2)). In the other cases, both tests were equally powerful. In addition, as seen above,
our test had a power close to that of the usual log-rank test when the patients were young
but showed a loss of power in scenarios 1 and 3 (Web Table B).
[Table 2 about here.]
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In the comparisons between the results of the stratified vs. the non-stratified version of
our test, in the case of two groups with dependence between TE and sex, the latter showed
less power (Table 3). The farther βsex was from 0, the greater was the loss of power. More
interestingly, as shown in Table 3, when the conditional distributions of TE were the most
different (HRsex = 3), the type I error was estimated at 2.95% (95% Confidence Interval
(CI) = [2.21; 3.69]) with the non-stratified version vs. 4.60% (95%CI = [3.68; 5.52]) with
the stratified version. However, when HRsex was equal to 2, the corresponding type I errors
were 4.80% (95%CI = [3.86; 5.74]) vs. 5.45% (95%CI = [4.46; 6.44]). Thus, the stratified
log-rank-type test is better used when the stratum variable has an important impact on net
survival.
[Table 3 about here.]
5. Application
For illustration, we used an application of our test to survival data on 10,108 patients
with colorectal cancer diagnosed in 1998. These data stem from 17 cancer registries of the
Surveillance, Epidemiology, and End Results (SEER) Program (2006) in the United States.
From this cohort, we excluded 816 patients who had no surgical procedure of the primary
site, 2 patients in whom the use of a surgical procedure was not certain, and 167 patients
with in situ tumors. Patient follow-up was restricted to the first five years after diagnosis
and the censoring set at five years in still-alive patients. These exclusions left 9,123 patients
for analysis. The covariates used were: age at diagnosis, sex, ethnicity (black or white), and
cancer stage at diagnosis (stages I to IV according to the stage classification of the American
Joint Committee on Cancer used by SEER registries (SEER Program: comparative staging
guide for cancer, 1993)). This dataset is described in Web Table C.
We used the American life tables provided by R software survexp.usr. These are stratified
14 Biometrics, 000 0000
by age, sex, ethnicity, and calendar year, from 1998 to 2003. All the analyses were carried
out with R (R Core Team, 2014). The code and the .RData files are available upon request.
We used our test to compare the net survival distributions between Black and White patients
as stratified on cancer stage (I to IV), which is known to have an important effect on cancer
net survival. Moreover, in the net survival framework, age is a strong prognostic factor
in several types of cancer (Bossard et al., 2007). We considered three age groups: adult
patients (20-69 years), old patients (70-79 years), and very old patients (> 80 years). These
stratifications led to 12 strata. Figure 1 shows the impact of age and, most importantly,
the impact of stage on net survival. First, the use of the non-stratified version of our test
gave a test statistic equal to 19.95 (p-value = 7.9 × 10−6). Second, running the test
with stratification on cancer stage, the test statistic was 5.42 (p-value = 0.0199). The
low proportion of Black patients with low cancer stages (47% in stages I-II vs. 56% for
White patients) suggested delayed diagnoses; however, after correction for this, the impact
of ethnicity on death from cancer remained significant and higher in Black than in White
patients. Third, running our test with stratification on age, the test statistic was 23.62
(p-value = 1.2 × 10−6). Whatever the age group, the differences in net survival between
Black and White patients were greater considering age strata than stage strata (data not
shown). Finally, running the test stratified on both age and cancer stage, the test statistic was
9.92 (p-value = 0.0016). Thus, not stratifying on stage overestimated the differences between
the net survival distributions of Black and White patients whereas not stratifying on age
underestimated these differences. Stratifying on both age and cancer stage provided “true”
differences vs. differences first distorted by group heterogeneity. Using the usual stratified
log-rank test on observed survival led to a test statistic equal to 19.5. Thus, the use of net
survival instead of observed survival allowed the removal of the confounding effect of age on
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observed survival.
[Figure 1 about here.]
6. Discussion
The proposed test compares distributions of net survival as estimated by the Pohar-Perme
estimator (Perme et al., 2012). The simulation study showed that the estimation of the type
I error is correct. Our test performed well in terms of power despite some loss of power in case
of elderly patient: this is because elderly patients have higher expected mortality rates than
young patients (i.e., are more at risk of death from other causes). In elderly populations, the
loss of information induces a higher variability in the estimates of net survival.
The stratified version is useful when dealing with covariates that exert strong impacts on
net survival; that is, when one or several covariates have different distributions in the groups
under comparison (see e.g., Aalen et al., 2008, p. 110-111). The decision to use the stratified
version should be based on epidemiological considerations depending on the covariates under
study. The application on real data showed that part of the difference in cancer net survival
between Black and White patients is due to differences in cancer stages.
In the test design, we adopted the set of assumptions of Perme et al. (2012). In particular, the
model assumed that two latent times defined on the same individual are dependent only via
measured covariates (assumption (1.c)). In practice, this may fail in the case of unmeasured
covariates (e.g., deprivation). In addition, we made assumptions (2) to prove the asymptotic
distribution of the statistic under the null hypothesis. These are reasonable assumptions
on the follow-up time because, according to these assumptions, the maximum follow-up T
should be small in comparison with TP given D or TE .
One possible limitation of our work is that we studied only simulations favorable to our
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test. Indeed, the usual log-rank test is optimal under the assumption of proportional hazard
rates but performs poorly when this assumption is not met (Qiu and Sheng, 2008). Several
approaches have been proposed to deal with this problem (see e.g., Fleming et al., 1980;
Mantel and Stablein, 1988 ; Breslow, Edler, and Berger, 1984; Qiu and Sheng, 2008). Actually,
further studies are needed to adapt our test to one of these procedures. In addition, the
formula we propose was developed with a continuous underlying process (without ties). In
our application, there were 46% of ties between event times because only survivals in months
were available from SEER. We studied the impact of the use of a non-tie-corrected version
of our test by using simulations that rounded the survival times to obtain 38%, 45%, and
54% of ties. To compare the percentages of rejection of the null hypothesis, the test was run
on the same dataset with and without ties: this led to a maximum difference of 2% (results
not shown). Thus, with such percentages of ties in the simulated settings, using a version
of the test not corrected for ties had hardly any impact. However a tie-corrected estimator
adapted from the one presented by Andersen et al. (1993) may be of interest.
Another option to compare distributions of net survival is to use regression modeling. We
compared our proposed test with the likelihood ratio test from the multivariate excess
mortality model using simulated datasets (both presented in section 4.1). We assumed a
perfectly defined excess mortality model; i.e., with adjustment on G and sex (whenever
necessary) with proportional effects (results not shown). In terms of power, the greatest
difference between the percentages of rejection of the null hypothesis by the two tests at
the 5% level of significance was 3.15% in favor of the likelihood ratio test. However, with a
generated and well-mastered dataset, and with the proposed test, we did not have to deal
with a model-building strategy (see e.g., Wynant and Abrahamowicz, 2014). Thus, our non-
parametric test should be preferred for its simplicity.
Because our test compares favorably with the usual log-rank test on hypothetical data (as
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shown in the simulation study), it may help cancer registries in comparing net survival from
cancer between countries or areas. In addition, it may be applied to other chronic diseases
in which the concept of net survival may be used. As already performed by Schoenfeld
(1981) on the usual log-rank test, it would be interesting to determine the distribution of the
proposed test statistic under the alternative hypothesis. By deriving Schoenfeld’s formula, we
may obtain the sample size that provides the minimal detectable difference. The equivalence
between the usual log-rank test and the score test from a Cox model is well known. Another
perspective would be to investigate whether such a relationship could exist in the net survival
setting. Introducing in a Cox model time-dependent weights that correspond to the ones used
in the Pohar-Perme estimator could be an interesting approach.
Supplementary Materials
Web Appendices and Tables referenced in Sections 2.3, 2.4, 4.2 and 5 are available with this
paper at the Biometrics website on Wiley Online Library.
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Figure 1. Net survival estimated by the Pohar-Perme estimator according to cancer stage
and age groups in White (dotted line) and Black (solid line) patients. When the excess
hazard is close to 0 and/or when the number of subjects at risk is low, the variability of the
Pohar-Perme estimator can cause non-monotonic net survival curves.
22 Biometrics, 000 0000
Table 1
Comparison between two groups: percentage of rejection of the null hypothesis at the 5% level of significance with
2000 simulations of 1000 patients. The age distribution is specific to each scenario: Scenario 1: 25% aged [40− 64],
35% aged [65− 74], and 40% aged [75− 85]; Scenario 2: 30 6 age 6 40 (uniform); Scenario 3: 65 6 age 6 80
(uniform).
HRa Percentage of rejection (95%CI)
Proposed test
Usual log-rank test on
hypothetical data
Scenario 1: balanced caseb
0.7 81.50 (79.80;83.20) 93.05 (91.94;94.16)
0.8 44.85 (42.67;47.03) 59.85 (57.70;62.00)
0.9 15.55 (13.96;17.14) 20.35 (18.59;22.11)
1 5.20 (4.23;6.17) 5.30 (4.32;6.28)
1.2 35.95 (33.85;38.05) 46.70 (44.51;48.89)
1.4 88.30 (86.89;89.71) 95.05 (94.10;96.00)
1.6 99.50 (99.19;99.81) 100 (99.81;100)
Scenario 2: balanced caseb
0.7 91.80 (90.60;93.00) 92.20 (91.02;93.38)
0.8 56.90 (54.73;59.07) 57.60 (55.43;59.77)
0.9 18.15 (16.46;19.84) 18.25 (16.56;19.94)
1 4.15 (3.28;5.02) 4.35 (3.46;5.24)
1.2 47.80 (45.61;49.99) 48.45 (46.26;50.64)
1.4 94.90 (93.94;95.86) 95.30 (94.37;96.23)
1.6 99.90 (99.64;99.97) 99.90 (99.64;99.97)
Scenario 3: balanced caseb
0.7 82.20 (80.52;83.88) 92.00 (90.81;93.19)
0.8 47.85 (45.66;50.04) 58.75 (56.59;60.91)
0.9 13.85 (12.34;15.36) 17.10 (15.45;18.75)
1 5.35 (4.36;6.34) 4.30 (3.41;5.19)
1.2 39.20 (37.06;41.34) 48.75 (46.56;50.94)
1.4 88.20 (86.79;89.61) 95.25 (94.32;96.18)
1.6 99.10 (98.69;99.51) 99.85 (99.56;99.95)
a: Hazard Ratio of the level of G to the excess mortality used in data generation, where G
is the covariate that represents the group.
b: Balanced cases correspond to cases where the groups are similar in size with
P (G = 0) = P (G = 1).
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Table 2
Comparison between three groups: percentage of rejection of the null hypothesis at the 5% level of significance with
2000 simulations of 1000 patients. The age distribution is that of Scenario 1 (25% aged [40− 64], 35% aged
[65− 74], and 40% aged [75− 85]).
(HR1, HR2)
a Percentage of rejection (95%CI)
Proposed test
Usual log-rank test on
hypothetical data
Scenario 1: balanced caseb
(1, 0.7) 66.75 (64.69;68.81) 82.90 (81.25;84.55)
(1, 1) 5.10 (4.14;6.06) 4.95 (4.00;5.90)
(1, 1.2) 26.20 (24.27;28.13) 35.80 (33.70;37.90)
(1, 1.4) 74.65 (72.74;76.56) 87.35 (85.89;88.81)
(1, 1.6) 97.20 (96.48;97.92) 99.70 (99.46;99.94)
(0.9, 1.2) 42.40 (40.23;44.57) 58.20 (56.04;60.36)
(0.8, 1.4) 96.10 (95.25;96.95) 98.90 (98.44;99.36)
(0.7, 1.6) 100 (99.81;100) 100 (99.81;100)
a: Hazard Ratios of the levels of G to the excess mortality used in data generation, where G
is the covariate that represents the group.
b: Balanced cases correspond to the cases where the groups are similar in size with
P (G = 0) = P (G = 1) = P (G = 2).
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Table 3
Comparison of between two groups: percentage of rejection of the null hypothesis at the 5% level of significance with
2000 simulations of 1000 patients when sex has an impact on the excess mortality in the data generation. The age
distribution is that of Scenario 1 (25% aged [40 − 64], 35% aged [65 − 74], and 40% aged [75− 85]).
HRa Percentage of rejection (95%CI)
Proposed test, stratified Proposed test, non-stratified
Scenario 1: HRsex = 2
0.7 90.60 (89.32;91.88) 88.55 (87.15;89.95)
0.8 57.90 (55.74;60.06) 53.25 (51.06;55.44)
0.9 18.00 (16.32;19.68) 16.40 (14.78;18.02)
1 5.45 (4.46;6.44) 4.80 (3.86;5.74)
1.2 46.50 (44.31;48.69) 43.50 (41.33;45.67)
1.4 95.00 (94.04;95.96) 93.35 (92.26;94.44)
1.6 99.90 (99.64;99.97) 99.85 (99.56;99.95)
Scenario 1: HRsex = 3
0.7 93.70 (92.74;94.76) 88.30 (86.89;89.71)
0.8 61.80 (59.67;63.93) 51.25 (49.06;53.44)
0.9 18.25 (16.56;19.94) 14.15 (12.62;15.68)
1 4.60 (3.68;5.52) 2.95 (2.21;3.69)
1.2 50.30 (48.11;52.49) 40.90 (38.75;43.05)
1.4 95.35 (94.43;96.27) 91.40 (90.17;92.63)
1.6 100 (99.81;100) 99.90 (99.64;99.97)
a: Hazard Ratios of the levels of G to the excess mortality used in data generation, where G
is the covariate that represents the group.
